ARTICLE | Clinical News

Tocosol: Phase IIa data

June 14, 2004 7:00 AM UTC

In a Phase IIa trial in 52 patients, 3 of 51 evaluable patients had complete responses and 17 had partial responses. Median time to disease progression was 24 weeks and the median survival has not yet...